Cite
HARVARD Citation
Dorn-Rasmussen, M. et al. (2022). Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease. Therapeutic drug monitoring. 44 (2), pp. 290-300. [Online].